ŠITINA, Michal and Vladimír ŠRÁMEK. Euglykemická ketoacidóza asociovaná se SGLT2 inhibitory a DPP4 inhibitory - rozbor kazuistik (Euglycemic ketoacidosis associated with SGLT2 inhibitors and DPP4 inhibitors - discussion of case reports). Anesteziologie a intenzivní medicína. Praha: Česká lékařská společnost J.E. Purkyně, 2024, vol. 35, No 2, p. 116-121. ISSN 1214-2158. Available from: https://dx.doi.org/10.36290/aim.2024.019.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Euglykemická ketoacidóza asociovaná se SGLT2 inhibitory a DPP4 inhibitory - rozbor kazuistik
Name (in English) Euglycemic ketoacidosis associated with SGLT2 inhibitors and DPP4 inhibitors - discussion of case reports
Authors ŠITINA, Michal (203 Czech Republic, belonging to the institution) and Vladimír ŠRÁMEK (203 Czech Republic).
Edition Anesteziologie a intenzivní medicína, Praha, Česká lékařská společnost J.E. Purkyně, 2024, 1214-2158.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30223 Anaesthesiology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.100 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.36290/aim.2024.019
UT WoS 001284895400006
Keywords (in Czech) glifloziny; SGLT2 inhibitory; euglykemická ketoacidóza; hyperchloremická acidóza; diabetes mellitus
Keywords in English gliflozins; SGLT2 inhibitors; euglycemic ketoacidosis; hyperchloremic acidosis; diabetes mellitus
Tags 14110518, rivok
Tags Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 21/8/2024 12:06.
Abstract
Euglycemic ketoacidosis is a rare but potentially fatal complication of treatment with SGLT2 inhibitors (gliflozins). However, similar euglycemic ketoacidosis may rarely occur with other antidiabetic drugs or conditions such as pregnancy or alcohol abuse. We describe 3 cases of our patients with euglycemic ketoacidosis associated with gliflozins and 1 case associated with the DPP4 inhibitor sitagliptin and discuss in detail the acid-base disturbances present and the distinction of euglycemic ketoacidosis from classical ketoacidosis in type 1 diabetes.
Abstract (in English)
Euglycemic ketoacidosis is a rare but potentially fatal complication of treatment with SGLT2 inhibitors (gliflozins). However, similar euglycemic ketoacidosis may rarely occur with other antidiabetic drugs or conditions such as pregnancy or alcohol abuse. We describe 3 cases of our patients with euglycemic ketoacidosis associated with gliflozins and 1 case associated with the DPP4 inhibitor sitagliptin and discuss in detail the acid-base disturbances present and the distinction of euglycemic ketoacidosis from classical ketoacidosis in type 1 diabetes.
PrintDisplayed: 14/9/2024 15:18